• 9th
    Aug, 2018
  • No Comments
  • Share Now

The Science Behind Psychedelic Substances

Today on Hempire Eileen is joined by Draulio B. de Araujo-Ph.D of Universidade Federal do Rio Grande. Draulio works as a professor of neuroscience at the Brain Institute in Natal, Brazil. His interests are related to the science behind psychedelic substances, such as ayahuasca, including recent randomized trials to test its antidepressant potential. They speak about how the en tropic brain hypothesis holds that the key facts concerning psychedelics are partially explained in terms of increased entropy of the brain’s functional connectivity. Ayahuasca is a psychedelic beverage of Amazonian indigenous origin with legal status in Brazil in religious and scientific

  • 20th
    Apr, 2018
  • No Comments
  • Share Now

Treating Alzheimer’s Disease Using Cannabis

Today on Hempire we are joined by James E Tripp from Ontario, Canada who treats his mother’s Alzheimer’s disease using cannabis. After a long struggle to get legal medical access his mother is now a licensed user, the medicine is delivered to the nursing home by a Licensed Producer, and it is administered by the medical staff. James also consults on cannabis therapy for other patients and makes medicines from raw plant materials. James worked for several years as a land surveyor and then in support services for a local hospital as well as running his own computer service business

  • 20th
    Apr, 2018
  • No Comments
  • Share Now

Cannabis Extract Treatment Protocols For Attention Deficit Disorder (ADHD)

Today on Hempire Dr. Eileen Karpfinger is joined by  Mara Gordon. Mara specializes in the development of cannabis extract treatment protocols for seriously ill patients in California. She is the co-founder of Aunt Zelda’s and Zelda Therapeutics. Prior to Aunt Zelda’s, Mara worked as a process engineer, helping Fortune 500 companies create intelligent software by utilizing the Rational Unified Process. This experience has enabled her to take a detailed and scientific approach to medical cannabis. Recognizing a need for patient-focused software, Gordon founded CDRMed. With CDRMed, physicians and medical health professionals are able to make treatment recommendations based on the

  • 20th
    Apr, 2018
  • No Comments
  • Share Now

The Potential Utility Of Cannabinoids For Treating AD

Today on Hempire Dr. Eileen Karpfinger is joined by Dr. Ester Aso. Dr. Aso has been working on the potential utility of cannabinoids for treating AD during the last 8 years. She has obtained promising results in animal models of the disease, suggesting that the combination of THC and CBD 1:1 at very low doses might reduce the progression of the disease. Now Dr. Aso setting up a phase II clinical trial funded by the Alzheimer’s Association (USA) with Sativex in patients in the very early stages of the AD (mild cognitive impairment). She still has no date to the

  • 14th
    Sep, 2017
  • No Comments
  • Share Now

Potential Therapeutic Effects of THC on Alzheimer’s Diseases

Potential Therapeutic Effects of THC on Alzheimer’s Diseases Dr. Eileen Karpfinger speaks with Sharlene Mavor, the Director of Medical Cannabis Research Australia. Mavor explains,” “We are just really keen to get clinical trials happening in Perth as it gets patients on medicinal cannabis within the trial setting, it will promote medicinal cannabis via the publicity even the announcement of a trial will cause, it will increase confidence in the medical community for its use and ultimately it will open up more qualifying conditions for general prescribing within Australia. Doctors are demanding good quality scientific evidence and this will provide it.